Anavex Life Sciences Corp (AVXL)

[RipperMagoo1]

Sorry to interrupt all the riveting Convid/Vax convos here on the AVXL board, but I had a question the upcoming Avatar "catalyst".

My understanding is that the Avatar study is essentially the exact same as the US Rett study except for the dosage and 2 more patients (n33 vs n31).

If above is true, then we can expect similar excellent clinically meaningful results. It's just a matter of how much better the higher dose performs.

Anavex PR'd on Dec 15th that the US Rett trial met primary & secondary endpoints. This took the stock from about $5 to $6. $1 or ~20% increase. I'm probably not the only one surprised how well this low dose performed. I think we can all agree this catalyst and the stellar results should have done much more to the sp.

My question is why most people, including our Honorable Judge Catalysts, saying this is a meaningful catalyst for big sp move? It's a forgone conclusion it will pass with flying colors as it's basically the same trial. Am I missing something here? Hoping I'm wrong but I'll be tempering my expectations of a sp rise when the top line results finally come in. Full PDD with actigraphy, full data of US Rett, or BTD (hope frrol is right here), AD enrollment all seem like much, much bigger catalysts to move the sp.


PS Arcadia vs Anavex - excellent comparison. Don't tell BioChecker4 shhh.

PPS In Falconer I Trust